Evaluation of the Cobas® 4800 HPV Test for the Detection of High-grade Cervical Disease in Women Undergoing Routine Cervical Cancer Screening Using Cervical Samples Prepared With the COBAS X421 Instrument
Interventional
Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Diagnostic
The clinical endpoint of greater than or equal to CIN2 includes histology results of CIN2, CIN3, cervical cancer, or ACIS
Study duration
No
Eric Fung
Study Director
Roche Molecular Systems, Inc
United States: Institutional Review Board
RD000649
NCT00709891
May 2008
June 2013
Name | Location |
---|---|
Hinsdale, Illinois 60521 | |
Albany, Georgia 31701 | |
Birmingham, Alabama 35294 | |
Phoenix, Arizona 85012 | |
Fountain Valley, California 92708 | |
Miami, Florida 33176 | |
Cleveland, Ohio 44195 | |
Philadelphia, Pennsylvania 19104 | |
Nashville, Tennessee 37203-1632 | |
Austin, Texas 78705 | |
Seattle, Washington 98195 | |
Flint, Michigan 48532 | |
Louisville, Kentucky 40207 | |
McLean, Virginia 22101 | |
Hackensack, New Jersey 07601 | |
Albuquerque, New Mexico 87131-5636 | |
Metairie, Louisiana 70006 | |
Denver, Colorado | |
Charlotte, North Carolina | |
Indianapolis, Indiana | |
Charleston, South Carolina | |
Las Vegas, Nevada 89109 | |
Salt Lake City, Utah 84112 | |
Coeur D'alene, Idaho 83814 |